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Abstract Nocturnal polyuria, nocturnal detrusor overactiv-
ity and high arousal thresholds are central in the pathogen-
esis of enuresis. An underlying mechanism on the
brainstem level is probably common to these mechanisms.
Enuretic children have an increased risk for psychosocial
comorbidity. The primary evaluation of the enuretic child is
usually straightforward, with no radiology or invasive
procedures required, and can be carried out by any
adequately educated nurse or physician. The first-line
treatment, once the few cases with underlying disorders,
such as diabetes, kidney disease or urogenital malforma-
tions, have been ruled out, is the enuresis alarm, which has
a definite curative potential but requires much work and
motivation. For families not able to comply with the alarm,
desmopressin should be the treatment of choice. In therapy-
resistant cases, occult constipation needs to be ruled out,
and then anticholinergic treatment—often combined with
desmopressin—can be tried. In situations when all other
treatments have failed, imipramine treatment is warranted,
provided the cardiac risks are taken into account.
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Introduction
Even though the days are long since passed when enuresis
was considered a neurotic disorder and the primary
treatment was psychotherapy—or no therapy at all—there
is still some controversy regarding both its pathogenesis
and treatment.
The purpose of this review is first to give a theoretical
background and then, based on this background, to provide
practical guidance. Throughout the text the new terminol-
ogy of the International Children’s Continence Society
(ICCS) [1] will be strictly adhered to, i.e. enuresis will be
taken to denote urinary incontinence while asleep in a child
aged at least 5 years.
Background: epidemiology, etiology and pathogenesis
Enuresis is a common condition. Approximately 5–10% of
7 year-olds regularly wet their beds [2], and the problem
may persist into teenage and adulthood. Boys are more
commonly afflicted than girls [2], and the condition tends
to run in families. There are three pathogenetic mechanisms
that have sufficient scientific support to be regarded as
important, namely, nocturnal polyuria, nocturnal detrusor
overactivity and high arousal thresholds. These may all, in
turn, be explained by a common underlying disturbance at
the brainstem level.
It is quite evident that there are bedwetting children
who produce disproportionately large amounts of urine at
night; this polyuria is often explained by a nocturnal lack
of the antidiuretic pituitary hormone vasopressin [3]. It is
also known that bedwetting can be provoked in some non-
enuretic children just by having them drink lots of water
before bedtime [4] and that the vasopressin analogue
desmopressin makes many bedwetters dry—especially the
ones with polyuria [5]. There are, however, some
important modifications to the hypothesis. First, not all
bedwetting children are polyuric [5]; second, some dry
children are polyuric (and have nocturia instead of
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children do not wake up.
Many enuretic children wet their beds not because their
bladders are full but because they suffer from nocturnal
detrusor overactivity. Indirect evidence for this is the great
overlap between nocturnal enuresis and urgency or urge
incontinence [7] and the fact that enuretic children—
especially the non-polyuric ones—void with smaller vol-
umes than non-enuretic children [8]. Direct proof comes
from ambulatory cystometries of children with therapy-
resistant enuresis [9].
It is often stated that the nocturnal bladder volume is
reduced in enuretic children. This statement is true but also
quite misleading. The bladder is not anatomically small, but
it tends to contract before it is full. Both bladder distension
and detrusor contractions are strong arousal stimuli [10].
Thus, the bedwetting child can be regarded as a “deep
sleeper” almost by definition, which is also supported by
the quite universal parental observation that their enuretic
children are difficult to wake up [11] as well as by studies
on objective arousal thresholds [12]. This does, however,
not mean that the sleep electroencephalogram (EEG) of
enuretic children is necessarily different from that of dry
children. This disorder of arousal may have underlying
brainstem explanations, or it may, paradoxically, be caused
by the arousal stimuli themselves. If somebody (in this
case, the full or overactive bladder) is always knocking at
the door, you end up by ignoring it or even installing an
extra lock.
In summary, the enuretic child (or adult) wets his/her bed
because either (1) bladder (over-)filling fails to wake him/
her up or (2) uninhibited detrusor contractions fail to wake
him/her up or (3) both.
Interestingly, there is increasing evidence that all three
mechanisms can be attributed to an underlying brainstem
disturbance. The locus coeruleus (LC), a noradrenergic
neuron group in the upper pons, is crucial for arousal
from sleep [13] and overlaps both functionally and
anatomically with the pontine micturition center [14],
which coordinates the micturition reflex. The LC also has
axonal connections with the hypothalamic cells that
produce vasopressin [15]. Evidence implicating a distur-
bance in this region of the brainstem in enuretic children is
accumulating [16, 17].
Finally, it is important to recognise that enuresis can,
in a minority of cases, be caused by other diseases.
Polyuric conditions such as diabetes—mellitus or insip-
idus—or nonoliguric renal failure are classical examples.
Most patients with these conditions do not become
enuretic [18], but some certainly do. Urinary tract
infection (UTI) can also cause enuresis or urge inconti-
nence, but most often the latter condition. The same is
even more true for constipation [19]. One reason for this
association is probably the fact that the filled rectum
compresses the bladder, causing detrusor overactivity.
The child with neurogenic bladder may certainly wet his/
her bed, but enuresis would probably not be the only
symptom. Among urinary tract malformations that may
cause enuresis, the urethral valves deserve special
mention. Those boys with urethral valve malformation
not only have a disturbed bladder function but also renal
tubular damage that leads to vicious circles of polyuria,
increased intravesical pressure and yet more renal
damage.
Enuresis may be caused by heavy snoring or sleep
apneas due to adenotonsillar hypertrophy. There are two,
non-exclusive, possible explanations for this: first, the
constant arousal stimuli from the obstructed airways causes
paradoxically high arousal thresholds and, second, the
negative intrathoracic pressure causes polyuria via in-
creased secretion of the atrial natriuretic peptide [20].
Treatment: theoretical considerations
The available antienuretic treatment alternatives can be
logically classified according to which underlying pathoge-
netic mechanism they address.
Desmopressin is a vasopressin analogue that retains the
hormone’s antidiuretic effects. It has been used for several
decades and has a proven antienuretic effect [21]. As a rule
of thumb, one third of unselected enuretic children are
reliably dry as long as they take the drug, one third has a
partial response and one third is not helped at all. It is
logical to assume that the reason for desmopressin’s
antienuretic effect is reduced urine production, and this
assumption is strongly supported by the fact that the
presence of nocturnal polyuria is a positive prognostic
indicator [8]. There is, however, also some evidence that
central nervous system effects may be active as well [22].
Desmopressin is remarkably free of risks and adverse
effects, even if used for months and years [23], but
potentially dangerous hyponatremia may result if the drug
is combined with excessive fluid intake [24].
The first-line treatment of daytime incontinence in
childhood is basic urotherapy, i.e. advice regarding fluid
intake and regular voiding habits. The same advice is
routinely given to enuretic children as well [25]. This is not
illogical, given the role of detrusor overactivity in enuresis,
but to date evidence for the efficacy of this approach is
weak [26–28]. However, urotherapy is certainly not
harmful and alleviates concomitant daytime symptoms.
It is also logical that anticholinergics, the established
second-line therapy against urge incontinence, have been
used in enuresis. The initial results have been only
modestly encouraging [29, 30], but there is now evidence
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an add-on therapy in enuretic children who have not
responded to desmopressin alone [31]. The drugs oxy-
butynin, tolterodine and propiverine are the most widely
used alternatives; they are not toxic but do carry a real risk
for constipation and for UTI due to the accumulation of
residual urine. In the case of oxybutynin, psychiatric side
effects are also not uncommon [32].
The inability to wake up from sleep is addressed by the
enuresis alarm. The underlying concept is simple: the first
drop of urine that reaches a detector in the bed or the
underclothes elicits a strong (usually acoustic) arousal
stimulus, thereby gradually teaching the patient to wake
up instead of wetting the bed. It is, however, still unclear
why the alarm works. And in fact, most of the enuretic
children who are successfully treated with the alarm do not
then start to wake up and exchange enuresis with nocturia
[33]. Despite this, the efficacy of such alarm treatment is
proven, the response rate varies between 50 and 80%
depending on the population chosen [34], and most
children successfully treated can be considered to be cured
[35]. Not surprisingly, the chance for successful alarm
therapy is greatest if the child and family are well
motivated.
The tricyclic antidepressant imipramine has been
successfully used as an antienuretic therapy. Placebo-
controlled studies give a response rate of approximately
50% [36]. The reason for this effect is also far from clear,
b u ti ti sm o s tl i k e l yt h a tt h ea n t i enuretic potential is linked
to brainstem noradrenergic action [37]. Imipramine is now
(hopefully) only used in severely therapy-resistant enure-
sis, since side effects—mostly mood changes, which can
be bothersome—are common, and overdosage can prove
fatal [38].
Finally, alternative treatment modalities, such as acu-
puncture and hypnotherapy, are often advocated. Sadly, the
evidence base for these therapies is, as yet, not firm enough
to warrant their use as standard therapies [39–41].
Comorbidity and consequences
All enuretic children do not grow out of their condition.
Prevalence figures for enuresis in adulthood vary between
0.5 and several percent [42, 43]. The risk for the enuresis
persisting into adulthood is highest in children who wet
their beds every night [44]. The enuretic child is also at risk
of developing other bladder problems, such as urge
incontinence, in adulthood [45, 46].
Furthermore, the psychosocial consequences of enuresis
can be grave. The links between the bladder and the soul
are problematic to disentangle due to the difficulty of
knowing what is cause, what is effect and what is
comorbidity without a direct causal relationship. However,
this much is clear:
1) Enuretic children suffer from low self-esteem as long
as they continue to wet their beds [47].
2) Enuresis—as well as daytime incontinence—is more
common among children with neuropsychiatric distur-
bances, such as attention deficit hyperactivity disorder
(ADHD) [48]. Among children with enuresis, approx-
imately 15% have ADHD, and vice versa [49, 50].
3) Enuretic children and adults have, in general, more
depressiveproblems andproblems at schoolandwork[43].
4) The enuretic children with highest risk for psychosocial
comorbidity are those with nonmonosymptomatic,
secondary or therapy-resistant enuresis [51].
Practical guidelines
The following recommendations are designed to be cost-
effective and applicable even in a situation with limited
healthcare resources. Extensive, time-consuming evaluations
are thus limited to children with suspected underlying
disorders and those who have proven to be therapy-resistant.
TheadviceisadaptedfromtheofficialICCSguidelinesforthe
evaluation of monosymptomatic enuresis [25].
Evaluation at the first visit
The first healthcare professional to see the enuretic child
may be a paediatrician, a general practitioner or a nurse.
What matters is that the person who sees the child knows
which questions to ask. The purpose of the first consulta-
tion is to detect whether extra evaluation or specialist
consultation is needed, to decide whether the child should
be treated at all, and then, optimally, start treatment. To
achieve this a basic case history and the results of a urine
dipstick test are needed. The history should focus on
general health, bladder and bowel habits and psychological
factors. A minimum list of suggested items is provided in
Table 1. The use of a proper bladder diary will substantiate
history data, help in the detection of bladder dysfunction
and detect families with poor compliance.
No radiology and no urodynamic investigations are
compulsory at this stage. Even a physical examination is not
necessary—provided the healthcare provider reacts to warn-
ing signs in the case history and/or the results of the urine test.
The relevant warning signs, and the actions to be taken if
present, are listed in Table 2. If none of these factors apply
and the child is old enough to be bothered by his/her
problems, then active treatment can be initiated. This
approach means that most children aged 6–7 years or older,
but only very few 5 year-olds, should be treated actively.
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If the child also suffers from bothersome daytime inconti-
nence this should be treated first. Otherwise, the first
treatment, for the family who is well-motivated and well-
informed, is the enuresis alarm. Desmopressin is the first-
line treatment for families who are not sufficiently
motivated to use the alarm, who have recently used the
alarm (correctly) without success or who are considered
unlikely to comply fully with alarm treatment. If measure-
ments of daytime voided volumes and nocturnal urine
production during “wet” nights (with weighing of diapers
or sheet covers) have been performed and the child is found
to have low voided volumes [maximum voided volume
<70% of the expected bladder capacity (30+30 × age mL)]
and no nocturnal polyuria (nocturnal urine production less
than 130% of the expected bladder capacity), then
desmopressin will probably not be useful.
Table 1 Relevant patient history at the first consultation
Areas of interest Relevance
General health and development
Growth, weight loss Poor growth in renal failure. Malaise, nausea,
weight loss etc in diabetes or kidney disease
Micturition and drinking habits
Bedwetting frequency Poor prognosis in very frequent enuresis
Previous dryness Comorbidity (somatic or psychiatric) more common in secondary enuresis
Daytime incontinence: When? How often? Urge incontinence should be treated before enuresis. Neurogenic
or anatomic causes gives daytime incontinence more often than isolated enuresis.
Urgency Indicates detrusor overactivity
Weak stream, hesitancy, straining These symptoms may indicate neurogenic bladder or malformation
Urinary tract infections Indicates lower urinary tract dysfunction, neurogenic bladder or
malformations, most commonly the former
Excessive thirst. Need to drink at night Kidney disease, diabetes or habitual polydipsia. Desmopressin contraindicated.
Bowel habits
Bowel movement frequency, stool consistency. Low stool frequency and/or hard stools indicate constipation,
which should be addressed before enuresis treatment can start
Faecal incontinence This is most commonly caused by constipation.
Psychology
Behavioral problems If behavioural problems are severe they may need to be addressed
concomitantly with enuresis therapy
How does the child view his/her enuresis? The child who is not bothered by the enuresis may not be motivated
for labour-intensive therapy
Table 2 Factors indicating that further evaluation is needed before the enuresis can be addressed
Warning signs Actions to be taken
Daytime incontinence or urinary tract infections. Make the family complete a frequency-volume chart before proceeding. Treat daytime
incontinence before enuresis.
Faecal incontinence, hard stools, unfrequent
bowel movements
Suspect, and treat for, constipation
Significant problems with peer relations and
behavior
Risk for therapy-resistance and/or psychiatric comorbidity. Consider parallel psychological
evaluation.
Straining, weak stream, continuous incontinence Suspect neurogenic bladder or anatomic abnormalities. Send to secondary center.
Glucosuria Consider diabetes mellitus. Check blood glucose immediately
Proteinuria (++ or more on urine test) Consider kidney disease. Consult paediatrician
Leukocyturia or nitrite test positive Take urine culture. Consider antibiotic treatment if culture is positive
Excessive thirst, need for night-time drinking Consider polydipsia or kidney disease. Measure fluid intake
Nausea, weight loss, fatigue Consider kidney disease. Check creatinine, hemoglobin and electrolytes and consult
paediatrician.
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alarm treatment:
1) A parent should sleep in the child’s room and help him/
her get up immediately when the alarm goes off. Very
often, the child will not be able to wake up by him/
herself during the first weeks of treatment.
2) Treatment needs to be continuous; no weekend alarm
holidays!
3) The instructor should provide frequent follow-up, with
a first phone call after 2 weeks, with the aim to provide
encouragement and solve technical problems.
4) Ifthereisnopositiveeffectafter6–8weeks,thentreatment
should be stopped. Otherwise, it should continue until 14
consecutive dry nights have been achieved.
If desmopressin treatment is chosen, it is recommended
that the oral quick-melt formula be used. The initial dosage
is 240 ug—to be taken 0.5–1 h before bedtime. A positive
effect will be seen directly; the lack of a beneficial effect
after 1–2 weeks of therapy means that treatment should be
stopped. If, on the other hand, the response is good, then
the dosage should be lowered to 120 ug to determine
whether this is enough to keep the child dry. Continuing
treatment—for those who respond—can be given every
night or just before “important nights” at the discretion of
the child and family. If continuous treatment is chosen, then
regular drug-free intervals should be interspersed to check
if the medication is still needed. In order to eliminate the
risk for hyponatremia, the child should be instructed to
limit fluid intake to a maximum of 2 dL from 1 h before
medication until the next morning. The only contraindica-
tion to desmopressin therapy is habitual polydipsia.
If the first choice of therapy, either the alarm or
desmopressin, did not work, then the other alternative
should be tried, but then first a full bladder diary with
measurements of noctunal urine production should be
completed. The child who has failed desmopressin therapy
and is now found to have nocturnal polyuria should
combine the alarm treatment with desmopressin to improve
the chance of success.
Evaluation of therapy-resistant children
If neither the alarm nor desmopressin has helped, then the
child needs to se a paediatrican or paediatric urologist and
undergo a general physical examination, including an exam-
ination of tendon reflexes and the lower back, in order to find
signs of spinal dysraphism. If a bladder diary has not been
completed before this step, it should be done now, including
measurements of nocturnal urine production.
Symptoms and signs of constipation should be actively
sought. A rectal examination should be performed if the
anamnesis gives any suspicion of constipation (infrequent
bowel movements, hard stools, faecal incontinence)—
provided the child and family are reasonably comfortable
with the procedure—since faeces in the ampulla recti is
almost pathognomonic.
The family also needs to be asked about the presence of
heavy snoring or excessive thirst (especially the need to
drink at night). Both fluid intake and creatinine as well as
urine osmolality should be measured in the child with
suspected polydipsia. The perceived reason for failure with
the enuresis alarm should also be asked for, since it is very
common that the family has not been given correct advice
(see above).
Uro-flow and residual urine measurements should be
performed in order to detect signs of outflow obstruction or
neuropathic bladder and to check for contraindications to
anticholinergic treatment (persistent residual urine).
Evaluation of the upper urinary tracts are usually not
indicated, but ultrasonographical measurement of the
horizontal rectal diameter is very useful [52]. A diameter
of more than 3 cm indicates constipation.
Cystometry, cystoscopy and further radiologic evalua-
tions are still not necessary, provided the above-mentioned
examinations do not reveal signs of neurological distur-
bance, renal damage or bladder outlet obstruction. Blood
tests will also not provide much useful information.
Secondary therapy
Constipation, if suspected, should be treated first as this
will either cause the enuresis to disappear or else make
other antienuretic therapies more likely to succeed.
Anticholinergic treatment is then the treatment of choice.
Although in many countries oxybutynin is currently the
only such drug registered for label use in children,
tolterodine is perhaps a better choice, since this drug has
fewer central nervous side effects. When more drugs have
been thoroughly tested in children, this recommendation
may change. Anticholinergic therapy has the greatest
chance of success in the child with signs of detrusor
overactivity, i.e. low daytime voided volumes. Before
anticholinergic treatment is started, constipation and resid-
ual urine need to be excluded or treated, and the family
should be instructed to look out for UTI symptoms.
Tolterodine can be used at a starting dosage of 2 mg,
regardless of age, given 1 h before bedtime. A positive
response will be seen within 1–2 months. If the response is
unsatisfactory but side effects are mild or absent, then the
dosage may be increased to 4 mg and desmopressin added
to the drug regimen. The successfully treated child should
taper therapy at least three to four times per year until he/
she stays dry without drug treatment. If treatment is initially
successful but later more and more wet nights start to
reappear, faecal impaction should be suspected and treated.
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or experience nocturnal apnoeas, tonsillectomy and/or
adenoidectomy should be considered as a possible
treatment.
The help of a psychologist or child psychiatrist should
be sought when it is suspected that there are behavioural
issues (ADHD, for instance) that make successful antienu-
retic therapy difficult or when the psychological problems
are grave enough to merit treatment regardless of the
enuresis. The child who is anxious or has a low self-esteem
because of the wetting is best treated by making him/her
dry!
If desmopressin, the alarm and the anticholinergic
treatment have all been tried without success, or have been
judged unsuitable, the cautious use of imipramine is
warranted. This is, however, a matter for specialist clinics
and not for the general paediatrician. Imipramine should
never be prescribed to a child with a history of unexplained
syncope/palpitations or with unstable arrhythmias or sud-
den cardiac death in the family without first ruling out long
QT syndrome (with a long-time electrocardiogram record-
ing). It is of utmost importance that the family keep the
drug securely under lock and key and that a dosage of 25–
50 mg, taken 1 h before bedtime, is not exceeded. Side
effects (mostly mood changes, which can be bothersome)
are common during the first weeks of therapy but often
recede without dosage adjustment. The anti-enuretic effect,
if any, is evident within 1 month. If the effect is partial,
desmopressin may be added to the therapeutic regimen. It is
important to take regular drug holidays to decrease the risk
of developing tolerance. One strategy is to take 2 weeks off
medication every 3 months, but some children need to do
this more frequently.
Finally, it is important to remember that the enuresis
alarm can, and should, be used again in children who are
therapy resistant or who need continuous medication to stay
dry. The fact that the alarm did not work 2 years previously
does not mean that it will not work this time. Likewise, a
new desmopressin trial in a previous nonresponder may
also be warranted.
Questions (Answers appear following the reference list)
1. Should a 5-year-old child be actively treated for
enuresis?
a Yes, enuresis is a socially handicapping condition
and should be treated early
b Usually not, but this depends on whether he/she is
bothered by the bedwetting or not
c Yes, enuresis is defined as bedwetting in a child 5
years old or more
d Yes, but treatment should start with desmopressin,
since the child is probably too young to be
motivated for alarm therapy
2. Why should imipramine not be a first-line therapy of
enuresis?
a We have insufficient evidence that it works
b It is not curative
c It is dangerous if overdosed
d Enuresis is not a psychiatric disorder and should
thus not be treated with antidepressants
3. Why is the enuresis alarm recommended as a first-line
therapy in enuresis?
a It is cheap
b It is curative
c It is evidence-based
d All of the above
e It is easy to use
4. Which of the following factors is not implicated by
modern research as crucial in the pathogenesis of
enuresis?
a Uninhibited micturition reflex
b Brainstem malfunction
c Nocturnal polyuria
d Neurosis
e Upper airway obstruction
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